Accurate prediction of CYP2D6 phenotype from genotype information is important to support
safe and efficacious pharmacotherapy with CYP2D6 substrates. To facilitate accurate …

Brexpiprazole is an oral antipsychotic agent indicated for use in patients with schizophrenia,
or as adjunctive treatment for major depressive disorder. As cytochrome P450 (CYP) 2D6 …

As a new atypical antipsychotic, brexpiprazole is primarily metabolized by cytochrome P450
3A4 (CYP3A4). However, genetic polymorphisms in CYP3A4 cause wide variability in …

Abstract Cytochrome P450 2D6 (CYP2D6) is an important drug‐metabolizing enzyme
exhibiting extensive interindividual variability predominantly caused by genetic …

Polymorphisms of cytochrome P450 (CYP) enzymes can affect enzymatic activity, drug
metabolism and drug interactions. Although the potential for drug interactions is especially …

Physiologically based pharmacokinetic (PBPK) modeling has a number of applications,
including assessing drug–drug interactions (DDIs) in polymorphic populations, and should …

Aim Rabeprazole is metabolized to some extent by CYP2C19. The purpose of this study was
to elucidate the pharmacokinetics of each rabeprazole enantiomer in three different …

Aims Rabeprazole is known to be a substrate of CYP2C19. Our objective was to evaluate
the possible effect of an inhibitor of CYP2C19, fluvoxamine, and compare the inhibitory …

Background: S‐mephenytoin 4'‐hydroxylase (CYP2C19) catalyses the metabolism of
rabeprazole to some extent. Based on the metabolic and pharmacokinetic differences …

Pantoprazole is used to treat gastroesophageal reflux disease (GERD), maintain healing of
erosive esophagitis (EE), and control symptoms related to Zollinger–Ellison syndrome …